Utility of different glycemic control metrics for optimizing management of diabetes
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
The benchmark for assessing quality of long-term glycemic control and adjustment of therapy is currently glycated hemoglobin (HbA1c). Despite its importance as an indicator for the development of diabetic complications, recent studies have revealed that this metric has some limitations; it conveys a rather complex message, which has to be taken into consideration for diabetes screening and treatment. On the basis of recent clinical trials, the relationship between HbA1c and cardiovascular outcomes in long-standing diabetes has been called into question. It becomes obvious that other surrogate and biomarkers are needed to better predict cardiovascular diabetes complications and assess efficiency of therapy. Glycated albumin, fructosamin, and 1,5-anhydroglucitol have received growing interest as alternative markers of glycemic control. In addition to measures of hyperglycemia, advanced glucose monitoring methods became available. An indispensible adjunct to HbA1c in routine diabetes care is self-monitoring of blood glucose. This monitoring method is now widely used, as it provides immediate feedback to patients on short-term changes, involving fasting, preprandial, and postprandial glucose levels. Beyond the traditional metrics, glycemic variability has been identified as a predictor of hypoglycemia, and it might also be implicated in the pathogenesis of vascular diabetes complications. Assessment of glycemic variability is thus important, but exact quantification requires frequently sampled glucose measurements. In order to optimize diabetes treatment, there is a need for both key metrics of glycemic control on a day-to-day basis and for more advanced, user-friendly monitoring methods. In addition to traditional discontinuous glucose testing, continuous glucose sensing has become a useful tool to reveal insufficient glycemic management. This new technology is particularly effective in patients with complicated diabetes and provides the opportunity to characterize glucose dynamics. Several continuous glucose monitoring (CGM) systems, which have shown usefulness in clinical practice, are presently on the market. They can broadly be divided into systems providing retrospective or real-time information on glucose patterns. The widespread clinical application of CGM is still hampered by the lack of generally accepted measures for assessment of glucose profiles and standardized reporting of glucose data. In this article, we will discuss advantages and limitations of various metrics for glycemic control as well as possibilities for evaluation of glucose data with the special focus on glycemic variability and application of CGM to improve individual diabetes management.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
Monnier, L., Lapinski, H., & Colette, C. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.881 · Cited by 1,461
Hanefeld, M., Fischer, S., Julius, U., Schulze, J., Schwanebeck, U., Schmechel, H., Ziegelasch, H. J., & Lindner, J. (1996) · Diabetologia · doi:10.1007/s001250050617 · Cited by 873
Barr, E. L. M., Zimmet, P. Z., Welborn, T. A., Jolley, D., Magliano, D. J., Dunstan, D. W., Cameron, A. J., Dwyer, T., Taylor, H. R., Tonkin, A. M., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.685628 · Cited by 719
A1C Variability and the Risk of Microvascular Complications in Type 1 Diabetes
Kilpatrick, E. S., Rigby, A. S., & Atkin, S. L. (2008) · Diabetes Care · doi:10.2337/dc08-0864 · Cited by 420
The effect of continuous glucose monitoring in well-controlled type 1 diabetes
Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group (2009) · Diabetes Care · doi:10.2337/dc09-0108 · Cited by 399
Assessing Glycemia in Diabetes Using Self-monitoring Blood Glucose and Hemoglobin A 1c
Saudek, C. D., Derr, R. L., & Kalyani, R. R. (2006) · JAMA · doi:10.1001/jama.295.14.1688 · Cited by 373
Cited by
Update on biomarkers of glycemic control
Krhač, M., & Lovrenčić, M. V. (2019) · World Journal of Diabetes · doi:10.4239/wjd.v10.i1.1 · Cited by 93
Pirbaglou, M., Katz, J., Motamed, M., Pludwinski, S., Walker, K., & Ritvo, P. (2018) · American Journal of Health Promotion · doi:10.1177/0890117118758234 · Cited by 83
The impact of glycemic variability on diabetic peripheral neuropathy
Jin, H. Y., Lee, K. A., & Park, T. S. (2016) · Endocrine · doi:10.1007/s12020-016-1005-7 · Cited by 49
Corazzari, C., Matteucci, M., Kołodziejczak, M., Kowalewski, M., Formenti, A. M., Giustina, A., Beghi, C., Barili, F., & Lorusso, R. (2022) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2021.05.035 · Cited by 36
Elissen, A. M. J., Hertroijs, D. F. L., Schaper, N. C., Bosma, H., Dagnelie, P. C., Henry, R. M., van der Kallen, C. J., Koster, A., Schram, M. T., Stehouwer, C. D. A., et al. (2017) · PLOS ONE · doi:10.1371/journal.pone.0182053 · Cited by 31
“Although there is growing interest in, amongst others, glycated albumin and fructosamin as alternative markers of glycaemic control, HbA1c remains the gold standard biomarker of glycaemia [12].”
Background
Metadata
- Authors
- Kohnert, K.-D.
- Venue
- World Journal of Diabetes
- Publisher
- Baishideng Publishing Group Inc.
- Published
- 2015
- Volume
- 6
- Issue
- 1
- Pages
- 17
- ISSN
- 1948-9358 (ISSN-L)
- OpenAlex
- W2032616907
- Cited by
- 94
- References
- 23
- FWCI
- 9.11
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Utility of different glycemic control metrics for optimizing management of diabetes. https://app.cochat.ai/papers/10.4239/wjd.v6.i1.17
- The paper
- Kohnert, K.-D. (2015). Utility of different glycemic control metrics for optimizing management of diabetes. World Journal of Diabetes. https://doi.org/10.4239/wjd.v6.i1.17
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.